Selected research
Industry Research
Peptide-Based Vaccines for Cancer Industry Research Report 2026
Market perspective
The global Peptide-Based Vaccines for Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Peptide-Based Vaccines for Cancer is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Peptide-Based Vaccines for Cancer is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Peptide-Based Vaccines for Cancer include ACT, Almac, AmbioPharm, Anergis, Immatics, Immatics, Marker Therapeutics, Inc., OncoPep and Sellas Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Peptide-Based Vaccines for Cancer market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide-Based Vaccines for Cancer Market by Company
ACT
Almac
AmbioPharm
Anergis
Immatics
Immatics
Marker Therapeutics, Inc.
OncoPep
Sellas Life Sciences
Ultimovacs
Peptide-Based Vaccines for Cancer Segment by Type
Synthetic Polypeptide Vaccines
Recombinant Polypeptide Vaccine
Other
Peptide-Based Vaccines for Cancer Segment by Application
Infectious Disease Prevention
Cancer Immunotherapy
Other
Peptide-Based Vaccines for Cancer Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Based Vaccines for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide-Based Vaccines for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Based Vaccines for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Peptide-Based Vaccines for Cancer manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Peptide-Based Vaccines for Cancer by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Peptide-Based Vaccines for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Synthetic Polypeptide Vaccines
- Recombinant Polypeptide Vaccine
- Other
Applications
- Infectious Disease Prevention
- Cancer Immunotherapy
- Other
Companies covered
- ACT
- Almac
- AmbioPharm
- Anergis
- Immatics
- Immatics
- Marker Therapeutics, Inc.
- OncoPep
- Sellas Life Sciences
- Ultimovacs
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Peptide-Based Vaccines for Cancer Market Size (2021-2032)
- 2.2.2 Global Peptide-Based Vaccines for Cancer Sales (2021-2032)
- 2.2.3 Global Peptide-Based Vaccines for Cancer Market Average Price (2021-2032)
- 2.3 Peptide-Based Vaccines for Cancer by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Synthetic Polypeptide Vaccines
- 2.3.3 Recombinant Polypeptide Vaccine
- 2.3.4 Other
- 2.4 Peptide-Based Vaccines for Cancer by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Infectious Disease Prevention
- 2.4.3 Cancer Immunotherapy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Peptide-Based Vaccines for Cancer Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Peptide-Based Vaccines for Cancer Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Peptide-Based Vaccines for Cancer Revenue of Manufacturers (2021-2026)
- 3.4 Global Peptide-Based Vaccines for Cancer Average Price by Manufacturers (2021-2026)
- 3.5 Global Peptide-Based Vaccines for Cancer Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Peptide-Based Vaccines for Cancer, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Peptide-Based Vaccines for Cancer, Product Type & Application
- 3.8 Global Manufacturers of Peptide-Based Vaccines for Cancer, Established Date
- 3.9 Global Peptide-Based Vaccines for Cancer Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ACT
- 4.1.1 ACT Company Information
- 4.1.2 ACT Business Overview
- 4.1.3 ACT Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ACT Peptide-Based Vaccines for Cancer Product Portfolio
- 4.1.5 ACT Recent Developments
- 4.2 Almac
- 4.2.1 Almac Company Information
- 4.2.2 Almac Business Overview
- 4.2.3 Almac Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Almac Peptide-Based Vaccines for Cancer Product Portfolio
- 4.2.5 Almac Recent Developments
- 4.3 AmbioPharm
- 4.3.1 AmbioPharm Company Information
- 4.3.2 AmbioPharm Business Overview
- 4.3.3 AmbioPharm Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio
- 4.3.5 AmbioPharm Recent Developments
- 4.4 Anergis
- 4.4.1 Anergis Company Information
- 4.4.2 Anergis Business Overview
- 4.4.3 Anergis Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Anergis Peptide-Based Vaccines for Cancer Product Portfolio
- 4.4.5 Anergis Recent Developments
- 4.5 Immatics
- 4.5.1 Immatics Company Information
- 4.5.2 Immatics Business Overview
- 4.5.3 Immatics Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
- 4.5.5 Immatics Recent Developments
- 4.6 Immatics
- 4.6.1 Immatics Company Information
- 4.6.2 Immatics Business Overview
- 4.6.3 Immatics Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
- 4.6.5 Immatics Recent Developments
- 4.7 Marker Therapeutics, Inc.
- 4.7.1 Marker Therapeutics, Inc. Company Information
- 4.7.2 Marker Therapeutics, Inc. Business Overview
- 4.7.3 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio
- 4.7.5 Marker Therapeutics, Inc. Recent Developments
- 4.8 OncoPep
- 4.8.1 OncoPep Company Information
- 4.8.2 OncoPep Business Overview
- 4.8.3 OncoPep Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 OncoPep Peptide-Based Vaccines for Cancer Product Portfolio
- 4.8.5 OncoPep Recent Developments
- 4.9 Sellas Life Sciences
- 4.9.1 Sellas Life Sciences Company Information
- 4.9.2 Sellas Life Sciences Business Overview
- 4.9.3 Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio
- 4.9.5 Sellas Life Sciences Recent Developments
- 4.10 Ultimovacs
- 4.10.1 Ultimovacs Company Information
- 4.10.2 Ultimovacs Business Overview
- 4.10.3 Ultimovacs Peptide-Based Vaccines for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio
- 4.10.5 Ultimovacs Recent Developments
5 Global Peptide-Based Vaccines for Cancer Market Scenario by Region
- 5.1 Global Peptide-Based Vaccines for Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Peptide-Based Vaccines for Cancer Sales by Region: 2021-2032
- 5.2.1 Global Peptide-Based Vaccines for Cancer Sales by Region: 2021-2026
- 5.2.2 Global Peptide-Based Vaccines for Cancer Sales by Region: 2027-2032
- 5.3 Global Peptide-Based Vaccines for Cancer Revenue by Region: 2021-2032
- 5.3.1 Global Peptide-Based Vaccines for Cancer Revenue by Region: 2021-2026
- 5.3.2 Global Peptide-Based Vaccines for Cancer Revenue by Region: 2027-2032
- 5.4 North America Peptide-Based Vaccines for Cancer Market Facts & Figures by Country
- 5.4.1 North America Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
- 5.4.3 North America Peptide-Based Vaccines for Cancer Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Peptide-Based Vaccines for Cancer Market Facts & Figures by Country
- 5.5.1 Europe Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
- 5.5.3 Europe Peptide-Based Vaccines for Cancer Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Peptide-Based Vaccines for Cancer Market Facts & Figures by Country
- 5.6.1 Asia Pacific Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Peptide-Based Vaccines for Cancer Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Peptide-Based Vaccines for Cancer Market Facts & Figures by Country
- 5.7.1 South America Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
- 5.7.3 South America Peptide-Based Vaccines for Cancer Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Peptide-Based Vaccines for Cancer Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Peptide-Based Vaccines for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Peptide-Based Vaccines for Cancer Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2032)
- 6.1.1 Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2021-2032)
- 6.2 Global Peptide-Based Vaccines for Cancer Revenue by Type (2021-2032)
- 6.2.1 Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2021-2032)
- 6.3 Global Peptide-Based Vaccines for Cancer Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2032)
- 7.1.1 Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2021-2032)
- 7.2 Global Peptide-Based Vaccines for Cancer Revenue by Application (2021-2032)
- 7.2.1 Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2021-2032)
- 7.3 Global Peptide-Based Vaccines for Cancer Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Peptide-Based Vaccines for Cancer Value Chain Analysis
- 8.1.1 Peptide-Based Vaccines for Cancer Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Peptide-Based Vaccines for Cancer Production Mode & Process
- 8.2 Peptide-Based Vaccines for Cancer Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Peptide-Based Vaccines for Cancer Distributors
- 8.2.3 Peptide-Based Vaccines for Cancer Customers
9 Global Peptide-Based Vaccines for Cancer Analyzing Market Dynamics
- 9.1 Peptide-Based Vaccines for Cancer Industry Trends
- 9.2 Peptide-Based Vaccines for Cancer Industry Drivers
- 9.3 Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges
- 9.4 Peptide-Based Vaccines for Cancer Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst